Exelixis (EXEL) Competitors

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Does the media favor BIIB or EXEL?

In the previous week, Biogen had 13 more articles in the media than Exelixis. MarketBeat recorded 47 mentions for Biogen and 34 mentions for Exelixis. Biogen's average media sentiment score of 1.16 beat Exelixis' score of 0.92 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	27 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	18 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, BIIB or EXEL?

Biogen has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Which has stronger earnings and valuation, BIIB or EXEL?

Biogen has higher revenue and earnings than Exelixis. Biogen is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.00B	2.02	$1.63B	$10.46	13.14
Exelixis	$2.17B	4.75	$521.27M	$2.08	18.41

Do institutionals & insiders hold more shares of BIIB or EXEL?

87.9% of Biogen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts recommend BIIB or EXEL?

Biogen presently has a consensus price target of $185.74, suggesting a potential upside of 35.13%. Exelixis has a consensus price target of $44.06, suggesting a potential upside of 15.03%. Given Biogen's higher probable upside, equities research analysts plainly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	21 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.34
Exelixis	1 Sell rating(s)	8 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.55

Is BIIB or EXEL more profitable?

Exelixis has a net margin of 27.01% compared to Biogen's net margin of 15.31%. Exelixis' return on equity of 27.47% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.31%	13.85%	8.32%
Exelixis	27.01%	27.47%	20.88%

Summary

Exelixis beats Biogen on 9 of the 16 factors compared between the two stocks.